In support of this hypothesis, high tumor expression of transcripts for the KLRK1, TNFRSF14, and CD160 NK cell receptors was associated with improved BLCA prognosis, suggesting that the expression of these NK cell receptor gene products by IL-2-expanded NK cells may be critical for BLCA antitumor immunity. The gene discussed is KLRK1; the disease is neoplasm.